http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107746432-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-21 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4711 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70 |
| filingDate | 2017-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107746432-B |
| titleOfInvention | A kind of Aβ42 modified protein and its expression and purification method |
| abstract | The invention belongs to the technical field of biotechnology and genetic engineering, in particular to an Aβ42 modified protein and a method for its expression and purification in Escherichia coli. The Aβ42 expression system constructed in the present invention provides a method for constructing a prokaryotic expression vector for expressing human amyloid Aβ42, and the expression vector is introduced into an Escherichia coli expression host. Active target Aβ42‑His protein. The large intestine expression system used in this method has the characteristics of high expression efficiency, large expression amount, low cost, easy operation, etc. The obtained Aβ42 polypeptide contains His tag to facilitate purification, and has high purity and high yield, which is more efficient than chemical synthesis of Aβ42. Advantages such as better aggregation properties and cytotoxicity. |
| priorityDate | 2017-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 135.